Evidence map›Paper›PMID 22294787›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2012

Role of RanBP9 on amyloidogenic processing of APP and synaptic protein levels in the mouse brain.

Madepalli K Lakshmana, Crystal D Hayes, Steven P Bennett, Elisabetta Bianchi, Konda M Reddy, Edward H Koo, David E Kang

RetractedErratum issuedOpen access · greenAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Structural and Functional Insights into GID/CTLH E3 Ligase Complexes.International journal of molecular sciences · 2022
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Mitochondrial dysfunction and calcium deregulation by the RanBP9-cofilin pathway.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013
    Article
  18. Article
  19. Article
  20. Protein phosphatase 1γ isoforms linked interactions in the brain.Journal of molecular neuroscience : MN · 2013
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 5 countries.

Madepalli K LakshmanaSection of Neurobiology, Torrey Pines Institute for Molecular Studies, Port Saint Lucie, Florida, USA. mlakshmana@tpims.org
Crystal D Hayes
Steven P Bennett
Elisabetta Bianchi
Konda M Reddy
Edward H Koo
David E Kang
Torrey Pines Institute For Molecular Studies · USUniversity of California, San Diego · USInstitut Pasteur · FRUniversity of Central Florida · US

Funding

Novel Mechanisms of RanBP9 in APP PathogenesisR01AG033055 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI KANG, DAVID E · 2009 to 2012
$1.2M
Role of RanBP9 on dendritic and spine injury in an Alzheimer's mouse modelR01AG036859 · NIA · TORREY PINES INST FOR MOLECULAR STUDIES · PI LAKSHMANA, MADEPALLI KRISHNAPPA · 2010 to 2013
$1.1M
LRP/RanBP9 Pathway in Alzheiimer's Disease PathogenesisK02AG031920 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI KANG, DAVID E · 2009 to 2011
$341k
Effect of RanbpM on amyloid pathology in a mouse model of Alzheimer's diseaseR03AG032064 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LAKSHMANA, MADEPALLI KRISHNAPPA · 2008 to 2009
$131k
NIA NIH HHS 1K02AG031920-10A1NIA NIH HHS 1R01AG033055-01A1NIA NIH HHS 1R01AG036859-01NIA NIH HHS 1R03AG032064-01NIA NIH HHS K02 AG031920NIA NIH HHS R01 AG033055NIA NIH HHS R01 AG036859NIA NIH HHS R03 AG032064
6 · The paper itself

Abstract

We previously reported that RanBP9 binds low-density lipoprotein receptor-related protein (LRP), amyloid precursor protein (APP), and BACE1 and robustly increased Aβ generation in a variety of cell lines and primary neuronal cultures. To confirm the physiological/ pathological significance of this phenotype in vivo, we successfully generated transgenic mice overexpressing RanBP9 as well as RanBP9-null mice. Here we show that RanBP9 overexpression resulted in >2-fold increase in Aβ40 levels as early as 4 mo of age. A sustained increase in Aβ40 levels was seen at 12 mo of age in both CHAPS-soluble and formic acid (FA)-soluble brain fractions. In addition, Aβ42 levels were also significantly increased in FA-soluble fractions at 12 mo of age. More important, increased Aβ levels were translated to increased deposition of amyloid plaques. In addition, RanBP9 overexpression significantly decreased the levels of synaptophysin and PSD-95 proteins. Conversely, RanBP9-null mice showed increased levels of synaptophysin, PSD-95, and drebrin A protein levels. Given that loss of synapses is the best pathological correlate of cognitive deficits in Alzheimer's disease (AD), increased Aβ levels by RanBP9 observed in the present study provides compelling evidence that RanBP9 may indeed play a key role in the etiology of AD. If so, RanBP9 provides a great opportunity to develop novel therapy for AD.

Indexed as

Adaptor Proteins, Signal TransducingAmyloid beta-Protein PrecursorAnimalsBrainCytoskeletal ProteinsEnzyme-Linked Immunosorbent AssayImmunohistochemistryMiceMice, TransgenicNerve Tissue ProteinsNuclear ProteinsSynapsesAdaptor Proteins, Signal TransducingAmyloid beta-Protein PrecursorCytoskeletal ProteinsNerve Tissue ProteinsNuclear ProteinsRan binding protein 9

Identifiers

PMID22294787
PMCPMC3336780
OpenAlexW2134897953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.